Muscadvance (Diclofenac Potassium)

Diclofenac potassium, the active ingredient in Muscadvance, is a nonsteroidal anti‑inflammatory drug (NSAID) presented as an oral dosage form for systemic use. It is indicated for relief of mild to moderate pain and for inflammatory musculoskeletal conditions in adults. GNH USA supplies Muscadvance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Diclofenac potassium is used to manage pain and inflammation across several musculoskeletal disorders. - Mild to moderate pain: provides analgesic relief for acute or chronic pain conditions. - Osteoarthritis: reduces joint pain and improves functional mobility. - Rheumatoid arthritis: helps control inflammatory joint swelling and stiffness. - Inflammatory musculoskeletal conditions: diminishes inflammation and associated discomfort.

Adverse reactions may occur with diclofenac potassium use.

Common Side Effects: - Gastrointestinal discomfort or dyspepsia - Nausea or vomiting - Headache - Dizziness - Skin rash or itching - Elevated blood pressure

Serious or Rare Side Effects: - Gastrointestinal ulcer or bleeding - Hepatic enzyme elevation or liver injury - Renal impairment or failure - Severe skin reactions such as Stevens‑Johnson syndrome - Cardiovascular events including myocardial infarction - Anaphylaxis or severe allergic reactions

Before initiating therapy, consider the following safety measures. - Assess renal function: adjust use in patients with impaired kidney function. - Monitor hepatic enzymes: avoid in severe liver disease. - Avoid in known hypersensitivity to diclofenac or other NSAIDs. - Use with caution in cardiovascular disease: increased risk of thrombotic events. - Limit alcohol consumption: may increase gastrointestinal bleeding risk. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Diclofenac potassium can interact with several drug classes.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Selective serotonin reuptake inhibitors (SSRIs): heightened gastrointestinal bleeding. - Lithium: reduced renal clearance, risk of toxicity. - Methotrexate: decreased excretion, possible toxicity. - Cyclosporine: additive nephrotoxicity.

Moderate Interactions (Monitor Closely): - ACE inhibitors: possible reduction in antihypertensive effect. - Diuretics: risk of reduced renal function. - Beta‑blockers: may mask tachycardia. - Corticosteroids: increased ulcer risk. - Alcohol: additive gastrointestinal irritation.